Quantcast

Latest Epratuzumab Stories

2010-11-09 07:05:00

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- UCB (EURONEXT: UCB) and U.S. based partner Immunomedics Inc. (Nasdaq: IMMU) announced that results from the phase IIb study, EMBLEM(TM), showed that certain doses of epratuzumab were associated with a meaningful and statistically significant* reduction in disease activity in adult patients with moderate to severe active SLE. The EMBLEM(TM) study was designed to evaluate the efficacy and safety of epratuzumab (in combination with immunosuppressants)...

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM(TM), suggest promising results of epratuzumab in patients with SLE. EMBLEM(TM) was a 12-week,...

2008-11-11 09:00:47

MORRIS PLAINS, N.J., Nov. 11, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Gerard G. Gorman, Senior Vice President, Finance and Business Development, and Chief Financial Officer, will be presenting at the Lazard Capital Markets 5th Annual Healthcare Conference to be held in New York City from November 18 - 19, 2008. Mr. Gorman's presentation,...

2008-10-27 15:00:09

SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- UCB (Euronext Brussels: UCB) announced data from two randomized controlled trials showing that treatment with epratuzumab a humanized anti-CD22 antibody, resulted in clinically meaningful reduced disease activity, improved health-related quality of life (HRQoL) measurements and reduced reliance on corticosteroids compared to placebo treatment in patients with active moderate and severe systemic lupus erythematosus (SLE). These findings were...

2008-10-14 09:00:11

MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S. patent 7,435,803 was issued today covering the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on...

2008-09-08 09:00:52

MORRIS PLAINS, N.J., Sept. 8, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that it will host a R&D day on Wednesday, September 17, 2008 from 9:30 am - 11:30 am EDT at the Waldorf Astoria Hotel in New York City. Featured presenters at the event will be Dr. John Leonard, the Richard T. Silver Distinguished Professor at Weill Cornell Medical...

2008-08-01 12:00:28

MORRIS PLAINS, N.J., Aug. 1, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced today that epratuzumab in combination with chemotherapy produced promising results in children with relapsed acute lymphoblastic leukemia (ALL), including 9 patients achieving a complete response. Results from this study were published in the August 1, 2008 issue of the Journal of...

2008-06-18 09:00:00

NEW ORLEANS, June 18, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today presented promising preclinical results on pretargeted therapy of pancreatic cancer that can be further improved when given in small fractions repeatedly, and in combination with gemcitabine. The pretargeted therapy involved TF10, a humanized bispecific antibody that binds to the same...

2008-06-17 15:01:05

NEW ORLEANS, June 17, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, described today at the 55th annual meeting of the Society of Nuclear Medicine a novel method for attaching fluorine-18 (F-18) to peptides, which in pretargeting studies using a human colorectal cancer model, produced exceptional positron emission tomography (PET) images. Direct labeling of F-18 to...

2008-06-16 12:00:00

NEW ORLEANS, La., June 16, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that pretargeting with a bispecific antibody (bsMAb) and a peptide labeled with gallium-68 (Ga-68), a positron emission tomography (PET) sensitive radioisotope, produced excellent images in a human colorectal cancer model. The bsMAb used in this study was TF2, an antibody...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related